Regeneron Pharmaceuticals

Trial and FDA signals

• New trial + clinical hiring Started a Phase 3 trial (NCT07697599, actual start Sep 7, 2026) (+9 other new trials); 101 clinical-operations roles open. ClinicalTrials.gov NCT07697599 (Sep 7, 2026)
  Evidence (10 events)

  • Sep 7, 2026 · ClinicalTrials.gov NCT07697599
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-09-07,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle='Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Centra'
  • Aug 26, 2026 · ClinicalTrials.gov NCT07493304
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-03-25; briefTitle='Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers'
  • Aug 10, 2026 · ClinicalTrials.gov NCT07626411
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-10,type:ACTUAL}; studyFirstPostDate=2026-06-04; briefTitle='Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07675811
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-06-30; briefTitle='A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctiviti'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07675824
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-06-30; briefTitle='REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07685808
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-06; briefTitle='Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes'
  • Jul 20, 2026 · ClinicalTrials.gov NCT07594106
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-20,type:ACTUAL}; studyFirstPostDate=2026-05-18; briefTitle='REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant'
  • Sep 17, 2026 · ClinicalTrials.gov NCT07759167
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-08-12; briefTitle='Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis'
  • Sep 8, 2026 · ClinicalTrials.gov NCT07543055
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-08,type:ACTUAL}; studyFirstPostDate=2026-04-21; briefTitle='A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Ha'
  • Oct 6, 2026 · ClinicalTrials.gov NCT07587658
    leadSponsor.name='Regeneron Pharmaceuticals'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-10-06,type:ACTUAL}; studyFirstPostDate=2026-05-14; briefTitle='This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants Afte'
• Drug approval + hiring FDA novel approval for PASATRU (BLA 761508, Aug 19, 2026); 266 manufacturing/quality or commercial roles open. FDA BLA 761508 (Aug 19, 2026)
  Evidence (1 event)

  • Aug 19, 2026 · FDA BLA 761508
    openFDA drugsfda: application_number=BLA761508; sponsor_name='REGENERON PHARMACEUTICALS, INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260819; submission_class_code=TYPE 1; brand_name=['PASATRU']

Job counts as of Oct 18, 2026. All trial and FDA signals